Skip to main content
Premium Trial:

Request an Annual Quote

Haplotypes Better than SNPs for Predicting Response to Cholesterol Drugs, Genaissance Researchers Find

NEW YORK, April 24-Researchers from Genaissance Pharmaceuticals have found that haplotypes are better than SNPs for predicting patient response to cholesterol-lowering drugs.

 

The finding is to be presented today at the American Heart Association Asia Pacific Scientific Forum.

 

In the study, researchers from Genaissance, Ruprecht Karls University, and Albert Ludwigs University identified 98 patients with high cholesterol. After initiating statin treatment, the researchers tracked changes in blood cholesterol and triglyceride levels. They also examined individual variations in the cholesteryl ester transfer protein (CETP) gene, which is thought to be involved in the balance between high- and low-density cholesterol levels, and tracked the activity of this gene during therapy.

 

The team found that while individual SNPS had little impact on gene expression or on drug efficacy, notable differences could be distinguished between patients with different haplotypes. For example, patients with two copies of one CETP haplotype showed a threefold increase in high-density cholesterol.

 

The effort is part of a larger Genaissance research project that is attempting to correlate patient genetic variations with the biological response to statin therapy. Genaissance hopes to develop markers that can guide clinicians in their drug-prescribing choices.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.